CASE REPORT article
Front. Neurosci.
Sec. Sleep and Circadian Rhythms
Case Report: PET/CT Assessment of Immunomodulatory Therapy in Anti-IgLON5 Encephalitis with Sleep Apnea
Provisionally accepted
- Chengdu Fifth People’s Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Anti-IgLON5 disease is a rare autoimmune neurological disorder characterized by sleep disturbances, movement disorders, cognitive decline, bulbar symptoms, and respiratory dysfunction, with a complex interplay between autoimmunity and neurodegeneration. Recent studies have provided insights into its clinical manifestations, immunological mechanisms, and potential therapeutic approaches. However, there is limited research on the diagnosis of Anti-IgLON5 disease and the assessment of immunomodulatory treatment effects from a metabolic perspective by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET-CT). This case describes a 59-year-old male presented with 1-year history of recurrent insomnia, low mood, staring spells, dysphagia, and choking while drinking water. Initially misdiagnosed with a gastrointestinal disorder or mental illness. The diagnosis was confirmed by positive serum and cerebrospinal fluid (CSF) tests for anti-IgLON5 antibodies, and 18F-FDG PET-CT showed abnormal FDG uptake in the medulla oblongata and left temporal lobe. After treatment with immunoglobulin pH4, mycophenolate mofetil tablets and corticosteroids significantly improved his condition. Follow-up at 3 months showed normalized metabolism on 18F-FDG PET-CT and improved sleep architecture. This case emphasizes the significance of anti-IgLON5 encephalitis in the differential diagnosis of complex sleep disorders, while also providing new insights and experiences regarding the evaluation of immune-modulatory therapy in the treatment of anti-IgLON5 encephalitis through 18F-FDG PET-CT. Overall, anti-IgLON5 disease is a multi-systemic condition that requires further research to identify precise and effective therapeutic strategies. Our case highlights the potential utility of 18F-FDG PET-CT in elucidating disease mechanisms and guiding clinical management.
Keywords: 18F-FDG, anti-IgLON5, Apnea, Autoimmune, case report, Encephalitis, Immunomodulatory therapy, PET-CT
Received: 08 Oct 2025; Accepted: 05 Feb 2026.
Copyright: © 2026 Liu, Luo, Jia, Lu, Yang, Fu, Guo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jia Guo
Zheng Li
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.